Perspectives

0:47
Patient monitoring following CAR T-cell therapy
Erik Aerts
1:06
The role of nurses in apheresis during CAR T-cell therapy
Erik Aerts
2:56
The future landscape of CAR T-cell therapy
Elaine Vickers
4:48
The quality control measures recommended within the JACIE model
Eoin McGrath
3:49
The limitations of immunotherapy with CAR T-cells
Elaine Vickers
0:48
HCP collaboration in CAR-T cell therapy
Erik Aerts
1:29
Settings for CAR T-cell therapy
Erik Aerts
3:07
CAR T-cell therapy: cancer immunotherapy beyond checkpoint inhibitors
Elaine Vickers
1:16
Uptake of CAR T-cell therapy in Europe
Duane Schulthess
1:24
The JACIE model for centers administering CAR T-cell therapy
Eoin McGrath
3:21
EMA initiatives on registries
Eoin McGrath
1:51
CAR T-cell therapy and transplantation for hematological malignancies
Arnon Nagler
2:22
CAR T-cell immunotherapy: current status and perspectives
Arnon Nagler
1:31
Christoph Röllig on AML research in Dresden, Germany
Christoph Röllig
2:25
The importance of genetic profiling: NGS, MRD & beyond
Tariq Mughal
4:15
Precision medicine in hematological oncology: development to the present day
Tariq Mughal
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals